Ambrisentan是一种口服活性、高选择性的内皮素受体ETA的选择性拮抗剂，IC50值为0.6nM。
Cas No.:177036-94-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ambrisentan is an orally active, highly selective antagonist of endothelin receptor ETA-selective antagonist, with an IC50 value of 0.6nM[1]. Ambrisentan inhibits the OATP1B1 and OATP1B3, with IC50 values of 47.0 and 44.6µM, respectively[2]. Ambrisentan has been widely used to improve liver function and hemodynamics in rat models of nonalcoholic steatohepatitis[3].
In vitro, Ambrisentan treatment at 50µM for 4 days significantly increased the mRNA levels of ABCB1 and CYP2C9 in LS180 cells[4]. Under hypoxic conditions, 0.02nM Ambrisentan treatment for 24h markedly enhanced autophagy in high glucose-treated human pulmonary artery endothelial cells (hPAECs)[5].
In vivo, Ambrisentan treatment via oral administration at a dose of 10mg/kg/day for 2 weeks significantly inhibited liver metastasis, reduced myeloid cell accumulation, and improved survival in 4T1 breast cancer-bearing mice[6]. Intraperitoneal injection of Ambrisentan at a dose of 5mg/kg/day for one week significantly reduced portal vein injury and alleviated biliary senescence in Mdr2-/- mice[7]. Oral administration of Ambrisentan at a dose of 2.5mg/kg/day for 4 weeks attenuated the progression of liver fibrosis without affecting steatosis in a mouse model of nonalcoholic steatohepatitis[8].
References:
[1] Hou J, Liu S, Zhang X, et al. Structural basis of antagonist selectivity in endothelin receptors[J]. Cell Discovery, 2024, 10(1): 79.
[2] Lepist E I, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes[J]. PloS one, 2014, 9(1): e87548.
[3] Bravo M, Raurell I, Barberá A, et al. Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH[J]. Disease models & mechanisms, 2021, 14(5): dmm048884.
[4] Weiss J, Herzog M, Haefeli W E. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro[J]. European journal of pharmacology, 2011, 660(2-3): 298-304.
[5] Cabiati M, Biondi F, Ghelardoni S, et al. Ambrisentan Retains Its Pro‐Autophagic Activity on Human Pulmonary Artery Endothelial Cells Exposed to Hypoxia in an In Vitro Model Mimicking Diabetes[J]. Journal of Cellular and Molecular Medicine, 2025, 29(7): e70528.
[6] Kappes L, Amer R L, Sommerlatte S, et al. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis[J]. Scientific reports, 2020, 10(1): 15931.
[7] Owen T, Carpino G, Chen L, et al. Endothelin receptor-A inhibition decreases ductular reaction, liver fibrosis, and angiogenesis in a model of cholangitis[J]. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16(4): 513-540.
[8] Okamoto T, Koda M, Miyoshi K, et al. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model[J]. World Journal of Hepatology, 2016, 8(22): 933.
Ambrisentan是一种口服活性、高选择性的内皮素受体ETA的选择性拮抗剂，IC50值为0.6nM[1]。Ambrisentan可抑制OATP1B1和OATP1B3，IC50值分别为47.0µM和44.6µM[2]。Ambrisentan已广泛用于改善非酒精性脂肪性肝炎大鼠模型的肝功能与血流动力学[3]。
在体外，使用50µM的Ambrisentan处理LS180细胞4天显著提高了ABCB1和CYP2C9的mRNA水平[4]。在低氧条件下，使用0.02nM的Ambrisentan处理高糖培养的人肺动脉内皮细胞（hPAECs）24小时显著增强了细胞自噬[5]。
在体内，以10mg/kg/day的剂量口服Ambrisentan，持续2周显著抑制了4T1乳腺癌荷瘤小鼠的肝转移，减少了髓系细胞积累并提高了生存率[6]。腹腔注射5mg/kg/day剂量的Ambrisentan连续一周，显著减轻了Mdr2-/-小鼠的门静脉损伤并缓解了胆道衰老[7]。以2.5mg/kg/day的剂量口服Ambrisentan，持续4周，在非酒精性脂肪性肝炎小鼠模型中减轻了肝纤维化的进展且不影响脂肪变性[5]。
| Cell experiment [1]: | |
Cell lines | Human pulmonary artery endothelial cells (hPAECs) |
Preparation Method | The hPAECs were seeded in 6-well petri dishes at a density of 2×105 cells/well. Hypoxia was induced by exposure to a mixture of 4% O2, 4% CO2, and 92% N2 at 37°C for 24 hours. Cells were divided into control glucose concentration (vehicle, 5.5mM, control and 285mOsm/l), high glucose concentration (HG: 30.5mM and 385mOsm/l), high mannitol concentration (HM: 5.5mM glucose+25mM and 385mOsm/l) for 24h, and were incubated under normoxic or hypoxic conditions with or without Ambrisentan (0.02nM). At the end of the treatment, cells were harvested for autophagy detection. |
Reaction Conditions | 0.02nM; 24h |
Applications | Ambrisentan treatment increased autophagy in hPAECs treated with high glucose under hypoxia/normoxia. |
| Animal experiment [2]: | |
Animal models | BALB/c mice |
Preparation Method | BALB/c mice were maintained in a standard sterile environment with a controlled 12-h light/dark cycle and ad libitum access to rodent feed and water. 4T1 cells (2×104 cells, volume 100µl) were subcutaneously injected into the fourth mammary fat pad of 8-week-old mice. Mice were randomly divided into two groups. The first group was treated with ddH2O by gavage daily for 5 days, followed by 2 days of rest for 2 weeks. The second group received Ambrisentan 10mg/kg/day for two weeks after tumor cell implantation. Mice were sacrificed on day 21 after implantation, and liver tissues were removed for analysis. |
Dosage form | 10mg/kg/day for 14 days; p.o. |
Applications | Ambrisentan treatment significantly reduced the liver metastatic foci in 4T1 breast tumor-bearing mice. |
References: | |
| Cas No. | 177036-94-1 | SDF | |
| 别名 | 安倍生坦; BSF 208075; LU 208075 | ||
| 化学名 | (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid | ||
| Canonical SMILES | CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C | ||
| 分子式 | C22H22N2O4 | 分子量 | 378.42 |
| 溶解度 | ≥ 18.921mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6426 mL | 13.2128 mL | 26.4257 mL |
| 5 mM | 528.5 μL | 2.6426 mL | 5.2851 mL |
| 10 mM | 264.3 μL | 1.3213 mL | 2.6426 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet